Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.
You may also be interested in...
Deals Of The Week: GSK/Cellzome, AZ/Torrent, Abbott/Facet Biotech...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
Deals Of The Week: GSK/Cellzome, AZ/Torrent, Abbott/Facet Biotech...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
Facet Says Yes To Abbott's $720 Million Buyout Offer
The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.